KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Work In Process (2018 - 2021)

BioNTech SE's Work In Process history spans 4 years, with the latest figure at $96.7 million for Q4 2021.

  • On a quarterly basis, Work In Process rose 317.92% to $96.7 million in Q4 2021 year-over-year; TTM through Dec 2021 was $96.7 million, a 317.92% increase, with the full-year FY2021 number at $96.7 million, up 317.92% from a year prior.
  • Work In Process hit $96.7 million in Q4 2021 for BioNTech SE, up from $67.2 million in the prior quarter.
  • Over the last five years, Work In Process for BNTX hit a ceiling of $96.7 million in Q4 2021 and a floor of $91311.7 in Q4 2018.
  • Historically, Work In Process has averaged $38.1 million across 4 years, with a median of $23.1 million in 2020.
  • Biggest five-year swings in Work In Process: skyrocketed 3400.86% in 2019 and later soared 317.92% in 2021.
  • Tracing BNTX's Work In Process over 4 years: stood at $91311.7 in 2018, then skyrocketed by 3400.86% to $3.2 million in 2019, then surged by 623.57% to $23.1 million in 2020, then soared by 317.92% to $96.7 million in 2021.
  • Business Quant data shows Work In Process for BNTX at $96.7 million in Q4 2021, $67.2 million in Q2 2021, and $23.1 million in Q4 2020.